Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis
References (18)
- et al.
A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis
Am J Surg
(1991) - et al.
Human pancreatic tissue concentration of bactericidal antibiotics
Gastroenterology
(1992) - et al.
Treatment of acute pancreatitis with Trasyrol: report of a controlled trial
Br Med J
(1965) - et al.
A single-centre double-blind trial of Trasyrol therapy in primary acute pancreatitis
Br J Surg
(1978) Morbidity of acute pancreatitis: the effect of aprotinin and glucagon
Gut
(1980)- et al.
A controlled trial of Trasyrol in the treatment of acute pancreatitis
Br J Surg
(1974) - et al.
Vascular changes of pancreatic ducts and vessels in acute necrotizing and in chronic pancreatitis in humans
Int J Pancreatol
(1991) - et al.
Contrast-enhanced computed tomography and microangiography of the pancreas in acute human hemorrhagic/necrotizing pancreatitis
Pancreas
(1988) - et al.
Effects of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction
Jpn J Gastroent
(1990)
Cited by (153)
Pharmacological Management of Acute and Chronic Pancreatitis
2022, Comprehensive PharmacologyClinical practice of acute pancreatitis in Japan: An analysis of nationwide epidemiological survey in 2016
2020, PancreatologyCitation Excerpt :Although the guidelines do not recommend antibiotic administration in mild AP cases, 94.5% of mild AP cases received antibiotics. In Japan, CRAI of protease inhibitors such as nafamostat mesylate has been commonly used in severe AP patients presenting hypoenhanced areas of the pancreatic parenchyma to maintain the high intrapancreatic concentrations of this reagent [31]. In this survey, CRAI of nafamostat mesylate did not reduce the mortality rate of severe AP cases, even in cases with extended hypoenhanced lesion of the pancreatic parenchyma.
Efficacy of recombinant human soluble thrombomodulin in preventing walled-off necrosis in severe acute pancreatitis patients
2015, PancreatologyCitation Excerpt :Enrolled patients were treated based on the strategy recommended in the Japanese guidelines for early stage acute pancreatitis [39–42]: in brief, fasting, aggressive fluid therapy, and administration of a protease inhibitor (nafamostat mesilate: 0.06–0.20 mg/kg/hours infused continuously; gabexate mesilate: 20–39 mg/kg/day). Continuous regional arterial infusion of the protease inhibitor (nafamostat mesilate) and prophylactic antibiotics (CRAI) [43–45] was undertaken for patients with ischemic or necrotizing pancreatitis [46,47]. Intravenous antibiotics were admitted for patients suspected to have sepsis (high fever with shock-like states).
Continuous regional arterial infusion for the treatment of severe acute pancreatitis: A meta-analysis
2015, Hepatobiliary and Pancreatic Diseases InternationalNafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
2021, Digestive Diseases and Sciences